Collegium Pharmaceutical Inc (COLL)
29.96
-0.45
(-1.48%)
USD |
NASDAQ |
Nov 22, 16:00
29.92
-0.04
(-0.13%)
After-Hours: 20:00
Collegium Pharmaceutical Cash from Financing (Quarterly): 149.03M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 149.03M |
| June 30, 2024 | -114.21M |
| March 31, 2024 | -54.15M |
| December 31, 2023 | -67.83M |
| September 30, 2023 | -95.41M |
| June 30, 2023 | -45.24M |
| March 31, 2023 | 68.30M |
| December 31, 2022 | -25.82M |
| September 30, 2022 | -31.25M |
| June 30, 2022 | -23.97M |
| March 31, 2022 | 517.76M |
| December 31, 2021 | -42.50M |
| September 30, 2021 | -26.51M |
| June 30, 2021 | -8.829M |
| March 31, 2021 | -11.47M |
| December 31, 2020 | -12.40M |
| September 30, 2020 | -12.03M |
| June 30, 2020 | -12.21M |
| March 31, 2020 | 323.12M |
| December 31, 2019 | 1.414M |
| September 30, 2019 | 0.407M |
| June 30, 2019 | 0.051M |
| Date | Value |
|---|---|
| March 31, 2019 | 0.169M |
| December 31, 2018 | -33.67M |
| September 30, 2018 | -33.07M |
| June 30, 2018 | -50.06M |
| March 31, 2018 | -0.388M |
| December 31, 2017 | 24.55M |
| September 30, 2017 | 9.309M |
| June 30, 2017 | -0.433M |
| March 31, 2017 | 0.05M |
| December 31, 2016 | 85.82M |
| September 30, 2016 | -0.194M |
| June 30, 2016 | -0.622M |
| March 31, 2016 | 50.55M |
| December 31, 2015 | -0.637M |
| September 30, 2015 | -0.265M |
| June 30, 2015 | 71.86M |
| March 31, 2015 | 45.04M |
| December 31, 2014 | 5.031M |
| September 30, 2014 | 5.993M |
| June 30, 2014 | -0.017M |
| March 31, 2014 | 1.031M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-114.21M
Minimum
Jun 2024
517.76M
Maximum
Mar 2022
23.79M
Average
-18.18M
Median
Cash from Financing (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 18.19M |
| Insmed Inc | 397.20M |
| Pulmonx Corp | 0.459M |
| RxSight Inc | 0.878M |
| Context Therapeutics Inc | -0.0446M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.999M |
| Cash from Investing (Quarterly) | -248.96M |
| Free Cash Flow | 192.43M |
| Free Cash Flow Per Share (Quarterly) | -0.2301 |
| Free Cash Flow to Equity (Quarterly) | -323.62M |
| Free Cash Flow to Firm (Quarterly) | -0.1872M |
| Free Cash Flow Yield | 13.99% |